Wall Street is positive on Day One Biopharmaceuticals Inc (DAWN). On average, analysts give the stock a Strong Buy rating. The average price target is $33, which means analysts expect the stock to climb by 235.71% over the next twelve months. That average ranking earns the stock an Analyst Rating of 73, which is better than 73% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating DAWN a Strong Buy today. Find out what this means to you and get the rest of the rankings on DAWN!